Delivery Order SPE2DB20D3103-SPE2DB25FP8U2
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $79,739.95 to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen injectors (2 ml units) on July 15, 2025, with completion expected by July 16, 2025. This competitively awarded, firm fixed-price contract contains no set-aside designation and is being performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a $16,998.05 delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen injectors on July 14, 2025, with completion scheduled for July 15, 2025. This competitively awarded, firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The delivery is scheduled to occur at AmerisourceBergen's...
- The Defense Logistics Agency awarded a $17,619.85 delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen injectors on July 23, 2025, with completion scheduled for July 24, 2025. This firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The work will be performed at AmerisourceBergen's corporate headquarters in...
- The Defense Logistics Agency awarded a delivery order valued at $38,528.12 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 ml pen injectors on June 18, 2025, with an ultimate completion date of June 20, 2025. This non-competitive, firm fixed-price delivery order will be fulfilled at the contractor's corporate office location in Conshohocken, Pennsylvania. The award represents a child delivery order issued under AmerisourceBergen's broader Indefinite Delivery Contract with...
- The Defense Logistics Agency awarded a $6,356.88 delivery order to AmerisourceBergen Drug Corp on July 23, 2025, for the supply of Dupixent 200 mg/1.14 ml pen injectors. This firm fixed-price delivery order, which is expected to be completed by July 24, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 through December 2026. The contract was competitively awarded with no set-aside...
- The Defense Logistics Agency awarded a delivery order valued at $5,389.54 to AmerisourceBergen Drug Corp for Dupixent (dupilumab) 300 mg/2 mL pen injectors on August 6, 2025, with completion expected by August 7, 2025. This competitively awarded, firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The pharmaceutical...
- The Defense Logistics Agency awarded a delivery order valued at $13,595.70 to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 mL pen injectors, with completion scheduled for May 21, 2025. The contract employs firm fixed price pricing with no set-aside designation, reflecting competitive procurement. AmerisourceBergen, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, serves as a critical vendor for federal medical procurement and operates as a child contract under...
- The Defense Logistics Agency awarded a delivery order valued at $5,987.47 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 ml pen injectors on August 5, 2025, with an ultimate completion date of August 6, 2025. This competitive award, issued under firm fixed pricing, represents a child contract to AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The place of...
- The Defense Logistics Agency awarded a delivery order valued at $15,733.89 to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen injectors, with performance in Conshohocken, Pennsylvania and completion targeted for September 11, 2025. This competitively awarded, firm fixed-price delivery order represents a non-set-aside procurement executed on September 10, 2025. The contract leverages AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL pen injectors, valued at $15,032.79 under a firm fixed-price contract. The order was awarded competitively without set-aside provisions on August 1, 2025, with an ultimate completion date of August 4, 2025. Performance of this delivery will occur at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract...
- SPE2DB20D3103Indefinite Delivery Contract
- SPE2DB20D3103-SPE2DB25FP8U2Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $22,972.76 to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 mL pen injectors on August 14, 2025, with completion expected by August 15, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and is performed at the vendor's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.999 billion comprehensive pharmaceutical prime vendor agreement running through December 2026 that enables the company to supply a full range of pharmaceutical products and medical supplies to support military healthcare programs globally. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, serves as a critical federal medical procurement vendor for military and veteran healthcare systems through the DLA Medical Supply Chain. The company's extensive federal contract portfolio demonstrates its capability to fulfill diverse pharmaceutical needs across multiple therapeutic domains, from specialty medications and brand-name drugs to vaccines and medical devices. This delivery order for Dupixent, a specialty biologic medication, exemplifies the vendor's role in supplying specialized healthcare commodities to support Defense Health Agency operations and other federal healthcare systems through flexible and competitive contract mechanisms.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $23.0k | 8/14/25 |